Abstract
Ursodeoxycholic acid is an important clinical drug in the treatment of liver disease. In our previous work, ursodeoxycholic acid was prepared by electroreduction of 7-ketolithocholic acid. The separation of ursodeoxycholic acid from the electroreduction product (47% (w/w) ursodeoxycholic acid) by silylation crystallization is described herein. N,N-dimethylformamide was used as the solvent, whereas hexamethyldisilazane was the reaction agent. The optimal material ratio of electroreduction product/N,N-dimethylformamide/hexamethyldisilazane was found to be 1:10:2 (w/v/v). The reaction proceeded for 2 h at 60°C, and the corresponding silylation derivative was separated by crystallization and pure ursodeoxycholic acid was recovered by 5% acid hydrolysis at 50°C for 0.5 h. The maximum recovery and purity of ursodeoxycholic acid were 99.8% and 99.5%, respectively. Ursodeoxycholic acid with high purity and high recovery can be prepared directly. The developed method offers a potential application for large-scale production of ursodeoxycholic acid.
Highlights
Ursodeoxycholic acid is an important clinical drug in the treatment of liver disease
Ursodeoxycholic acid (3α, 7β-2-hydroxy-5β-cholanic acid, UDCA) is an important clinical drug used in the treatment of liver disease, such as gallstones [1], alcoholic fatty liver [2], nonalcoholic fatty liver [3], viral hepatitis [4], primary biliary cirrhosis [5], primary sclerosing cholangitis [6], and cholestatic [7]
These results indicate that the silylating reagent has an important effect on the recovery and purity of UDCA
Summary
Ursodeoxycholic acid is an important clinical drug in the treatment of liver disease. UDCA was prepared by electroreduction of 7-ketolithocholic acid (3α-hydroxy-7oxo-5β-cholanic acid, 7K-LCA) [9]. UDCA and its epimer chenodeoxycholic acid (3α, 7α-2-hydroxy-5βcholanic acid, CDCA) were both reduction products of 7K-LCA; the product of this electrochemistry conversion was a mixture of 7K-LCA, UDCA, and CDCA, which are difficult to separate. This problem limits its application in the production of UDCA.
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
